Section 1. Eligibility Criteria
Rationale: The study population is comprised of Veteran patients with end stage renal disease (ESRD) on dialysis with evidence of VHA care within the past 365 days. Patients were eligible for entry into in the study at the first date at which they showed evidence of both ESRD and dialysis during the study period (2007 until 2013, inclusive) . This is considered the initial eligibility date used to pull data for our population out of the Corporate Data Warehouse (CDW). Two stages of inclusion criteria were implemented. The first was to extract patients from the CDW and the second was to determine hospital admissions that met inclusion criteria for our study. The unit of analysis was the hospital admission for patients with evidence of ESRD and dialysis within six months of their hospitalization. Additional exclusion criteria were applied in relation to the hospitalization to rule out alternative explanations for anemia
A. Clinical Concept: ESRD
Rationale: Patients with ESRD generally suffer from disease related anemia, which is subject to treatment by ESAs or alternatively RBC transfusions. For this reason, the study defined patients as eligible for inclusion if they had evidence of ESRD and use of dialysis.
Tables:
1 1. Study Period (to determine patient eligibility) 2. 6 months prior to admission (to determine hospitalization inclusion criteria) Vocabulary: ICD9 procedure codes Rationale: A record of dialysis was used as part of the eligibility criteria as a marker to confirm the diagnosis of ESRD and to ensure patients were receiving dialysis treatment in the VA. PROCEDURE OTHER THAN HEMODIALYSIS (EG, PERITONEAL DIALYSIS,  HEMOFILTRATION, OR OTHER CONTINUOUS RENAL REPLACEMENT THERAPIES), WITH  SINGLE PHYSICIAN EVALUATION   90945   DIALYSIS PROCEDURE OTHER THAN HEMODIALYSIS (EG, PERITONEAL DIALYSIS,  HEMOFILTRATION, OR OTHER CONTINUOUS RENAL REPLACEMENT THERAPIES)  REQUIRING REPEATED PHYSICIAN EVALUATIONS, WITH OR WITHOUT SUBSTANTIAL  REVISION OF DIALYSIS PRESCRIPTION   90947   END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PER  FULL MONTH, FOR PATIENTS YOUNGER THAN 2 YEARS OF AGE TO INCLUDE  MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND  DEVELOPMENT, AND COUNSELING OF PARENTS   90963   END-STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS PER  FULL MONTH, FOR PATIENTS 2-11 YEARS OF AGE TO INCLUDE MONITORING FOR THE  ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND  COUNSELING OF PARENTS   90964   END-STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS PER  FULL MONTH, FOR PATIENTS 12-19 YEARS OF AGE TO INCLUDE MONITORING FOR THE  ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND  COUNSELING OF PARENTS   90965   END-STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS PER  FULL MONTH, FOR PATIENTS 20 YEARS OF AGE AND OLDER   90966   DIALYSIS TRAINING, PATIENT, INCLUDING HELPER WHERE APPLICABLE, ANY MODE,  COMPLETED COURSE   90989   HEMODIALYSIS TRAINING AND/OR COUNSELING  90990  HOME HEMODIALYSIS CARE, OUTPATIENT, FOR THOSE SERVICES EITHER PROVIDED  BY THE PHYSICIAN PRIMARILY RESPONSIBLE FOR TOTAL HEMODIALYSIS CARE OR  UNDER HIS DIRECT SUPERVISION, AND EXCLUDES CARE FOR COMPLICATING  ILLNESSES UNRELATED TO HEMODIALYSIS, ON MONTHLY BASIS   90991   PERITONEAL DIALYSIS TRAINING AND/OR COUNSELING  90992  SUPERVISION OF CHRONIC AMBULATORY PERITONEAL DIALYSIS (CAPD), HOME OR  OUT-PATIENT (MONTHLY)   90994 UNLISTED DIALYSIS PROCEDURE, INPATIENT OR OUTPATIENT 90999 HOME VISIT FOR HEMODIALYSIS  99512  HOME INFUSION OF PERITONEAL DIALYSIS, PER VISIT  99559  TRAVEL TIME FOR HOME DIALYSIS EQUIPMENT REPAIR PER MILE  A4830  LABOR CHARGES FOR HOME DIALYSIS EQUIPMENT REPAIR PER HOUR  A4840  PLUMBING AND/OR ELECTRICAL WORK FOR HOME HEMODIALYSIS EQUIPMENT  A4870  END STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS  PATIENTS PER FULL MONTH; FOR PATIENTS UNDER TWO YEARS OF AGE TO INCLUDE  MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND  DEVELOPMENT, AND COUNSELING OF PARENTS   G0320   END STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS  PATIENTS PER FULL MONTH; FOR PATIENTS TWO TO ELEVEN YEARS OF AGE TO  INCLUDE MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH  AND DEVELOPMENT, AND COUNSELING OF PARENTS   G0321   END STAGE RENAL DISEASE ( ESRD ) RELATED SERVICES FOR HOME DIALYSIS  PATIENTS PER FULL MONTH; FOR PATIENTS TWELVE TO NINETEEN YEARS OF AGE TO  INCLUDE MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF A. GI bleed: We defined GI Hemorrhage using IV PPI (a common treatment for GI bleed) and positive guaiac tests (a test for the presence of GI bleed) during the hospital stay and 3 weeks prior to hospitalization. a. IV PPI: Hospitalizations with an IV administered OrderableItem with a name containing the terms "Lansoprazole", "Omeprazole", "Pantoprazole", "Rabeprazole", or "Esomeprazole" between three weeks prior to admission and the day of discharge (inclusive) were excluded from the study. After the LOINC codes were queried, and lab test names reviewed, the following logic was used to restrict to HGB and HCT specific tests. Topographies were intended to reflect blood, serum or plasma, and contained any of the following: "bld", "blood", "venous", "arterial", "erythrocyte", "plasma", "serum" and did not contain any of the following: "urine" or "fluid." Accepted lab test names contained any of the following: "hemoglobin", "hgb", "thb", "hematocrit", "hct", but did not include any of the following: "pulse oxim", "fhhb", "reticulocyte", "occult."
Tables: 1. CDW Lab Chemistry Timeframe: Anemia had to occur +/-24 hours from admission Vocabulary: LOINC Transfusion orders were also allowed to occur prior to admission but after anemia.
Vocabulary: ICD9 procedure codes, CPT/HCPCS codes, orderable items, MCA feeder keys
RBC Transfusion Identification using CDW ICD9 and CPT

ICD9 Procedures
The below ICD9 procedures were considered evidence of RBC transfusions. These records were found in the CDW inpatient data domain. 
CPT/HCPCS Procedures
The below CPT/HCPCS codes were considered evidence of RBC transfusion. These records were found in the CDW inpatient and outpatient data domains. Note that in VHA, outpatient procedures may occur during inpatient stays (prior to discharge). 
Orderable Items
The below Orderable Items were considered evidence of RBC transfusion. These codes represent orders for RBC transfusions, regardless of whether they were carried out. Chart review revealed that inclusion of these codes increased sensitivity to RBC transfusions, but decreased specificity. Orderable Items were not allowed to have associated status of: "pending", "cancelled", "unreleased", or "expired". 
RBC Transfusion Identification using MCA
Background: MCA VA"s cost allocation system, the Decision Support System (DSS), now known as the MCA system, generates cost data on VA hospital stays and health care encounters using programs that run on pre-existing VA relational databases to provide information to managers and physicians. Cost of intermediate products, such as units of blood, are evaluated by MCA programs.
1 MCA collects data in the outpatient and inpatient settings. 2 Tables within the MCA domain were used because the DSS application software inherently compares records to VBECS for use in the Laboratory Blood Bank (LBB) Comparative Report. The LBB compares information from the VBECS DSS EXTRACT file with blood bank records reported to DSS. 3 We examined two of the many MCA tables to identify RBC transfusions: the event capture system (ECS) and Laboratory (LAB) tables. 1 The LAB table contains information on a patient"s laboratory test . 4 MCA feeder keys in these tables which contain information about the product extracted by MCA. 3 We found that a few of the feeder keys identified as records of RBC transfusion administration showed a high degree of correlation with the blood product key found in CAPRI, which provides read access to the blood bank data.
Selection of MCA Feeder Keys representing RBC transfusions
To identify potentially relevant feeder keys, data from the ECS and LAB tables were queried within one day prior to admission, and two days after admission. Records with procedure or test names containing "transfus", "Red Blood Cell", "RBC", "blood product", "blood bank", and "VBECS" were selected for review. Also reviewed were cases where the feeder key or associated name contained a CPT code identified previously as evidence of RBC transfusion. A clinician reviewed the feeder keys and corresponding procedure/test names. In the event of questionable procedure/test names, a manual review of patient records with the respective feeder key was performed using CAPRI. This allowed us to view VBECS records and the associated blood product keys to determine if a questionable feeder key was representative of a RBC transfusion. Feeder keys associated with a RBC transfusion and approved by clinician review were included in our code set for the identification of RBC transfusion (Table 12) .
We determined that feeder keys associated with procedure/test names containing terms related to "ABO", "Count", "Fresh Frozen Plasma", "Folate", "Indices", "Lysate" "Panel", "RBA", "Request", and "Saline" were not representative of a RBC transfusion. Some of these terms indicate the wrong concept (e.g. fresh frozen plasma), while others indicate the wrong topography (e.g. Urine), and others indicate a type and cross (e.g. ABO). Type and cross records were not included because they did not always indicate the blood product was administered and did not provide a consistent record of RBC transfusions. Some of these terms were added as a result of clinician review. AS-3 RBC 04761 PHERESIS) AS = Additive Solution, RBC = Red Blood Cell, LR = LEUKOCYTES REDUCED, IRRIrradiated, CPD = citrate-phosphate-dextrose, CPDA = citrate-phosphate-dextrose-adenine *Values are reported as they exist in the database, this includes misspelled and unfinished words *Some acronyms are not listed because they are specific to MCA DSS or VBECS domains Section 2. Clinical Algorithm TRA Rationale: The clinical algorithm (CA) was created to identify a TRA using data that is not typically available in historical CMS (discussed in Section 3). For our study, this applies to hemoglobin laboratory values, as well as data used in our exclusion criteria which included internal VHA concepts found in the surgical package to identify surgery, IV package to identify Proton Pump Inhibitor administration, and laboratory to identify positive guaiac test results. The CA defines a TRA as hospital admission in a population of ESRD (Section 1A) patients who have had dialysis (Section 1B), where there is evidence of anemia (HGB < 9.0 mg/dL or HCT < 27 %) (Section 1D) and a RBC transfusion (Section 1E) in the absence of exclusion criteria (Section 1C). Anemia was required to occur +/-24 hours before or after admission. Evidence of a RBC transfusion had to occur after anemia and during the first 24 hours of the admission. We allowed RBC transfusion orders (Table 11 ) to also account for RBC transfusion administration in order to increase sensitivity. Orders for a RBC transfusion were included as evidence of administration due to our inability to access VBECs blood bank database, which contains all records of RBC transfusion administration in the VA. 5 Full definitions are described in sections above.
CAs data definitions described in the sections above:
 CA ESRD (Section 1A)
Section 3. Claims Based TRA
Claims algorithms rationale, definitions and limitations
Rationale: Four Claims Based Algorithms (CBA) were defined and used as exploratory measures, designed to detect TRA/TRA-Primary in claims based data typical of Centers for Medicare and Medicaid Services (CMS) Inpatient Research Identifiable Files using key features also present in VA data. This would provide a framework for those who do not have access to clinical data to apply similar TRA/TRA-primary detection procedures to claims data, using validated algorithms. Note that some exclusion criteria involved data that may not be available in claims data and must be taken into consideration when transporting these algorithms to CMS or commercial databases.
Key Features -VA Data to CMS Inpatient Research Identifiable Files for TRA identification:
 Principal discharge diagnosis code (reason for the admission)  Secondary diagnosis codes  Procedure codes  CMS "present on admission" was not included into CBA because the VHA does not contain a direct equivalent  RBC transfusions were allowed to occur on the day of admission or the day after admission
Limitations: As described above, the process we used allowed us to mimic information found in the CMS Inpatient Research Identifiable files using VA data. However, there are limitations to the direct application of these algorithms to CMS data. CBAs should be applied with caution and validation in a CMS or commercial setting. Nevertheless, the rationale and justification are consistent with how one would implement the algorithms. Also, note that we used additional clinical data in our exclusion criteria that may not be contained in other data sets.
Defining CBA components: CBA used various terminology resources to detect the occurrence of TRA/TRA-Primary.
The following definitions are used to define the various CBAs.  RBC transfusion: A RBC transfusion on date of admission or the following date, as coded in ICD9 (Table 9) or CPT/HCPCS (Table 10 ) procedure codes, product administration orders (Table 11) or DSS feeder keys (Table 12 )  CKD: a principal or secondary ICD9 discharge diagnosis of CKD (see Table 13 below)  Anemia: a principal or secondary ICD9 discharge diagnosis of anemia (see Table 14 below)
Tables:
CDW Inpatient Discharge Diagnoses Timeframe:
 CKD Diagnosis -On discharge date  RBC Transfusion -On date of admission or the following date  Anemia diagnosis -On discharge date Vocabulary: ICD9 Diagnosis codes 
Claims algorithms and Concept Comparisons
Rationale: Different coding practices led us to create four claims algorithms to identify TRA and TRA-primary. Each algorithm was applied to each definition to determine the best identifier in claims data. Claims algorithms are described in Table 15 below. 6 While this change in protocol bolstered the amount of clinical data available, it only accounted for patients who received an ESA. This protocol was subsequently changed in the 2011 CMS Quality Incentive Program (QIP) which required all ESRD facilities to include hemoglobin/hematocrit values in their claims submission on or after January 12, 2012, regardless of ESA use. While more laboratory data was collected by CMS post-2011 this was not always the case during the course of our study period. 7 We believed that inclusion of the CMS laboratory data would have created an incomplete picture given the difference in reporting policies across our study period, so we chose to code anemia only with available ICD9 codes (Table 14) . Also, as mentioned by Wang et. al, CMS receives only one hemoglobin value each month for each patient"s hemodialysis, which may not represent the patient"s true hemoglobin status for the entire month. 8 However, given the availability of CMS laboratory data, the procedures described in the CA can be adjusted to run on more recent claims data. If this is done, the limitations described in Section 3.1 above should be considered.
Section 4: Sampling
Rationale: We found that TRA and TRA-primary accounted for only a small portion of our study population. This low prevalence necessitated sampling strategies that specially account for imbalanced data. This problem typically occurs when there is an extremely unequal distribution between classes of interest in the data, and one class is vastly underrepresented in comparison to the rest. When normal sampling schemes are applied to such data, it is highly unlikely that the underrepresented group will be selected unless much larger sample is used. Extremely low prevalence of a class of interest also affects the reliability of estimates like accuracy, in which case a substitute value known as the geometric mean is a viable substitute. 9, 10 To account for this we devised a sampling strategy that supported populationlevel estimates of algorithm performance and at the same time provided insight into where errors may be occurring with the CA.
Sampling Strategy:
To define the different classes of interest used for sampling, we used variations of the CA, aimed at identifying a TRA and areas of potential error in our CA. This created four classes used in sampling the first was the basic definition of the CA as described in Section 2, used to define a TRA, along with three variations on the same concept. With a target accuracy statistically indistinguishable from 90% at the alpha=.05 level, we needed to sample at least 150 hospitalizations from sampling rule 1 for the lower end of the 95% confidence interval to be at least 85%. To achieve this required value as well as account for imbalanced data, we randomly sampled without replacement 400 hospitalizations from sampling rule 1, 200 from sampling rule 2, 200 from sampling rule 3 and 100 from sampling rule 4. The sample from rule 4 was small as we did not expect errors with this rule. Each rule is described in detail below. The 900 was randomly divided into four batches of 225 for review. To allow reviewer comparison, 10 charts from each reviewer were also reviewed by the other, for a total overlap of 20 charts. We used the first batch of 225 chart-review hospitalizations for error analysis and refinement of the CA and the exclusion criteria to adjust our algorithms as described below. After adjustment, 533 unique hospital admissions remained were used for the validation study and reported results.
Sampling rule 1:
Is the primary class of interest and representative of the potential occurrence of a TRA in the data. This sampled class is the CA described in Section 2. It required evidence of anemia (HGB < 9.0 mg/dL or HCT < 27 %) (Section 1D) 24 hours prior to admission AND a RBC transfusion (section 1E) within the first 24 hours after admission. Reviewers determined the presence or absence of a TRA and TRA-primary during validation. During validation, if reviewers determined that the patient did not have ESRD-related anemia with a RBC transfusion within the defined time frames, or they showed evidence of exclusion criteria (Section 1C), this signaled the potential need to adjust our algorithms. This sampling class is representative of a true positive if correctly identified.
Sampling rule 2:
Created to identify errors with our RBC transfusion definitions (Section 1E), it required evidence of anemia 24 hours prior to admission, with no evidence of a RBC transfusion within the first 24 hours after admission. During validation, if reviewers identified the occurrence of a transfusion in this class this signified the potential need to adjust our algorithms. This sampling class is representative of a true negative if correctly identified, as it is not a TRA or TRAprimary.
Sampling rule 3:
Created to identify errors with our anemia data definitions (Section 1D), it required no evidence of anemia (HGB ≥ 9mg/dL or HCT ≥ 27%) between 24 hours prior to admission and 24 hours after admission, AND evidence of a RBC transfusion within the first 24 hours after admission. During validation, if reviewers identified the occurrence of anemia (HGB < 9.0 mg/dL or HCT < 27 %) in this class this signified the potential need to adjust our algorithms. This sampling class is representative of a true negative if correctly identified, as it is not a TRA or TRAprimary.
Sampling rule 4:
Created to ensure we were correctly identifying patients who did not have any of the criteria of a TRA. This differs from the previous two values which are aimed at identifying partial TRA concepts to help identify sources of improvement in the algorithms. It required no evidence of anemia on admission AND no evidence of a RBC transfusion during the first 24 hours of the admission. During validation, if reviewers identified the occurrence of a transfusion or anemia in this class this signified the potential need to adjust our algorithms. This sampling class is representative of a true negative if correctly identified, as it is not a TRA or TRAprimary.
Section 5: Statistical Estimate of Population-Level Parameters
Rationale: We intended to statistically evaluate the performance of each CA and CBA, with respect to the detection of TRAs. To do this, we had to make special considerations due to the sampling mechanism and the rare prevalence of RBC transfusions. The sampling mechanism described in Section 4 was implemented due to the rarity of RBC transfusions in the population, and resulted in four samples that, when combined incorrectly, would produce biased statistical estimates for the population (with the singular exception of positive predictive value (PPV), as screening positive was only possible for sampling rule 1). To obtain unbiased estimates for the population, we implemented inverse probability weighting (IPW) based on the probability of sampling from each sampling rule. As mentioned previously, the geometric mean (g) of sensitivity (SE) and specificity (SP) was considered an appropriate metric because the outcome is rare 9 , and we wished to evaluate the effectiveness of the CA and CBAs based on their properties, rather than properties which are highly influenced by prevalence, such as accuracy.
Methods
Statistics calculated:
Using chart review results, we calculated several statistics for each algorithm: SE, SP, g, accuracy, PPV, negative predictive value (NPV), and incidence of TRA. These statistics were calculated using the TRA and TRA-primary RBC transfusion definitions. Sample-level statistics as well as population-level statistics were calculated, but sample-level statistics have not been reported because of the known bias.
Confidence intervals (CI) were calculated for each statistic. To obtain population-level estimates, all statistics were bootstrapped. Bootstrapping results in an approximately normal empirical distribution for each statistic, with an easily calculated mean and standard deviation, but calculating a 95% CI using this normal assumption for boundary values with high variance resulted in estimates that violated the boundaries on the statistics calculated (e.g. some were > 100%). To account for this, we performed a logit transformation to estimate all confidence intervals.
11
Note about incidence: Incidence of TRA is uniform across tests because it reflects the weighted incidence for each of the four sampling rules, based on chart review results for TRA and TRA-primary. This is independent of each test.
Estimating Statistics using bootstrapped IPW:
: The total number of hospitalizations in sample rule ; : The number of hospitalizations sampled from rule ; : ⁄ , The probability of sampling each hospitalization in sample rule ; : , The weight for sample i; : The number of true positives among ; : The number of false positives among ;
